-
公开(公告)号：US08293719B2
公开(公告)日：2012-10-23
申请号：US13043228
申请日：2011-03-08
申请人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
发明人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
CPC分类号： C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
摘要： The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
摘要翻译： 本发明的特征涉及用于调节血管内皮生长因子（VEGF）表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 所述化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。
-
公开(公告)号：US08084031B2
公开(公告)日：2011-12-27
申请号：US12268459
申请日：2008-11-11
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2842 , A61K2039/505 , C07K16/2821 , C07K16/2839 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
摘要翻译： 公开了治疗炎症性疾病的方法，特别是治疗关节炎。 该方法包括施用能够结合VLA-1表位的功能阻断抗体。
-
公开(公告)号：US07919473B2
公开(公告)日：2011-04-05
申请号：US11340080
申请日：2006-01-25
申请人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
发明人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
CPC分类号： C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
摘要： The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
摘要翻译： 本发明的特征涉及用于调节血管内皮生长因子（VEGF）表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。
-
公开(公告)号：US20050025768A1
公开(公告)日：2005-02-03
申请号：US10855013
申请日：2004-05-27
IPC分类号： C07K16/24 , G01N33/53 , A61K39/395
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention provides antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides cells producing the antibodies, and methods of making and using the same.
摘要翻译： 本发明提供结合多种β-趋化因子，特别是单核细胞趋化蛋白MCP-1，MCP-2和MCP-3的抗体。 本发明还提供产生抗体的细胞，以及制备和使用该抗体的方法。
-
公开(公告)号：US20130065943A1
公开(公告)日：2013-03-14
申请号：US13612521
申请日：2012-09-12
申请人： Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
发明人： Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
IPC分类号： C12N15/113 , A61P25/00 , A61P37/00 , C12N15/63 , A61P31/14 , A61P31/20 , C12N5/071 , A61K31/713 , A61P31/16
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/113 , C12N2310/14 , C12N2310/17 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
摘要翻译： 本发明涉及用于抑制CD45基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US08344130B2
公开(公告)日：2013-01-01
申请号：US13355903
申请日：2012-01-23
申请人： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
发明人： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
CPC分类号： C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
-
17.发明授权Polynucleotides encoding members of the human B lymphocyte activation antigen B7 family and polypeptides encoded thereby 失效编码人B淋巴细胞活化抗原B7家族成员的多核苷酸和由此编码的多肽公开(公告)号：US07968680B2
公开(公告)日：2011-06-28
申请号：US11943501
申请日：2007-11-20
IPC分类号： C07K14/705 , A61K38/17
CPC分类号： C07K14/70532 , A61K38/00 , Y10S435/81
摘要： The present invention provides novel isolated BLAA polynucleotides and the membrane-associated or secreted polypeptides encoded by the BLAA polynucleotides. Also provided are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant or fragment of the BLAA polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BLAA polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
摘要翻译： 本发明提供新的分离的BLAA多核苷酸和由BLAA多核苷酸编码的膜相关或分泌的多肽。 还提供了免疫特异性结合BLAA多肽或BLAA多肽，多核苷酸或抗体的任何衍生物，变体，突变体或片段的抗体。 本发明另外提供了其中BLAA多肽，多核苷酸和抗体用于检测和治疗广泛范围的病理状态以及其它用途的方法。
-
公开(公告)号：US07737265B2
公开(公告)日：2010-06-15
申请号：US11477028
申请日：2006-06-27
申请人： Akin Akinc , Antonin De Fougerolles , Hans-Peter Vornlocher , Philipp Hadwiger , Birgit Bramlage
发明人： Akin Akinc , Antonin De Fougerolles , Hans-Peter Vornlocher , Philipp Hadwiger , Birgit Bramlage
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3521
摘要： The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1α, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
摘要翻译： 本发明的特征涉及用于调节HIF-1α表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。
-
公开(公告)号：US20090324598A1
公开(公告)日：2009-12-31
申请号：US12268459
申请日：2008-11-11
IPC分类号： A61K39/395
CPC分类号： C07K16/2842 , A61K2039/505 , C07K16/2821 , C07K16/2839 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
摘要翻译： 公开了治疗炎症性疾病的方法，特别是治疗关节炎。 该方法包括施用能够结合VLA-1表位的功能阻断抗体。
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.065 秒)
